Equities analysts expect Johnson & Johnson (NYSE:JNJ) to announce $2.01 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Johnson & Johnson’s earnings, with estimates ranging from $1.88 to $2.08. Johnson & Johnson reported earnings of $1.83 per share in the same quarter last year, which would indicate a positive year over year growth rate of 9.8%. The firm is expected to announce its next quarterly earnings results before the market opens on Tuesday, April 17th.
On average, analysts expect that Johnson & Johnson will report full year earnings of $8.11 per share for the current fiscal year, with EPS estimates ranging from $8.08 to $8.20. For the next year, analysts forecast that the company will post earnings of $8.63 per share, with EPS estimates ranging from $8.40 to $8.97. Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating the Zacks’ consensus estimate of $2.01 by $0.05. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The firm had revenue of $20.01 billion for the quarter, compared to analysts’ expectations of $19.50 billion. During the same quarter in the previous year, the business posted $1.83 EPS. The company’s quarterly revenue was up 12.6% on a year-over-year basis.
A number of analysts have recently commented on JNJ shares. BTIG Research restated a “sell” rating and set a $110.00 target price on shares of Johnson & Johnson in a report on Wednesday, January 24th. Vetr cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $147.40 target price on the stock. in a report on Monday, January 8th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. Wells Fargo restated an “outperform” rating and set a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Finally, TheStreet cut shares of Johnson & Johnson from an “a” rating to a “c+” rating in a report on Monday, March 26th. Five investment analysts have rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $144.23.
In related news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.22% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Goodman Financial Corp purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $104,000. Stelac Advisory Services LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $108,000. Harding Loevner LP purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $106,000. Mountain Capital Investment Advisors Inc purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $124,000. Finally, Financial Gravity Companies Inc. purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $143,000. Institutional investors and hedge funds own 67.23% of the company’s stock.
Shares of JNJ stock traded down $2.14 during mid-day trading on Thursday, reaching $129.62. 7,608,596 shares of the company’s stock traded hands, compared to its average volume of 7,896,124. Johnson & Johnson has a 12 month low of $120.95 and a 12 month high of $148.32. The stock has a market cap of $350,440.66, a PE ratio of 17.77, a price-to-earnings-growth ratio of 2.08 and a beta of 0.74. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51.
ILLEGAL ACTIVITY WARNING: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/17/brokerages-anticipate-johnson-johnson-jnj-to-post-2-01-eps.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.